Erianin, a MEK-CRAF inhibitor, was reported to suppress the constitutive activation of the MAPK signaling pathway and exhibit anti-tumor effects in melanoma and colorectal cancer PDX models [50]. Here, RAF1 is linked to colorectal cancer.